Nama's AI scorecard currently rates Cytokinetics Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does CYTK report earnings?

Cytokinetics's next scheduled report is on Feb 24, 2027. Analysts expect EPS of -$1.39.

What is the CYTK price target?

The median analyst price target from 18 analysts is $106.00, with a range of $81.00 – $140.00.

Is CYTK Shariah compliant?

Nama's AAOIFI-style screen reads Cytokinetics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Cytokinetics (CYTK)

Healthcare · Biotechnology · NASDAQ

Cytokinetics (CYTK) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $7.48B and a free-cash-flow yield of -8.3%. Over the most recent reported fiscal year, revenue grew 376.6%. Nama's AI scorecard rates it Sell, 3.0 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Sell · 3.0/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Middle · +1.4% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-51.3%

How far the last close sits under the highest price of the past five years.

Market cap	$7.48B
Trailing P/E	—
Price / book	—
Price / sales	109.6
FCF yield	-8.3%
Dividend yield	—
Gross margin	-212.9%
Operating margin	-1046.1%
Net margin	-1321.1%
Revenue growth (YoY)	+376.6%
Revenue growth (3-yr annual)	-2.4%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.4
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

CYTK earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate -$1.39). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	-$1.37	-$1.41	+2.8%	$47.56M
Q2 2026	Aug 6, 2026	-$1.50	-$1.60	+6.2%	$28.62M
Q1 2026	May 5, 2026	-$1.67	-$1.65	-1.2%	$19.36M
Q4 2025	Feb 24, 2026	-$1.50	-$1.37	-9.5%	$17.75M

CYTK analyst price target

Median target $106.00 from 18 analysts, ranging $81.00 – $140.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live CYTK data on Nama Insights →

Recent Congressional trades

Cytokinetics trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Oct 12, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Jul 2, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Nov 18, 2025
Lisa McClain	House	Sell	$1,001 - $15,000	Aug 13, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025

CYTK FAQ

Is CYTK a buy?: Nama's AI scorecard currently rates Cytokinetics Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does CYTK report earnings?: Cytokinetics's next scheduled report is on Feb 24, 2027. Analysts expect EPS of -$1.39.
What is the CYTK price target?: The median analyst price target from 18 analysts is $106.00, with a range of $81.00 – $140.00.
Is CYTK Shariah compliant?: Nama's AAOIFI-style screen reads Cytokinetics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.